Abbott Laboratories (ABT) Cash from Investing Activities (2009 - 2026)

Abbott Laboratories has disclosed Cash from Investing Activities across 18 years of filings, most recently posting -$673.0 million for Q2 2026.

• In Q2 2026, Cash from Investing Activities fell 15.64% year-over-year to -$673.0 million; the TTM figure through Jun 2026 stood at -$22.4 billion (down 790.41% YoY), while the FY2025 annual figure was -$2.4 billion, down 3.59% from the prior year.
• Cash from Investing Activities came in at -$673.0 million for Q2 2026 at Abbott Laboratories, up from -$20.3 billion in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of -$264.0 million in Q2 2022 to a low of -$20.3 billion in Q1 2026.
• Average Cash from Investing Activities over 5 years is -$1.7 billion, with a median of -$588.0 million recorded in 2024.
• Year-over-year, Cash from Investing Activities surged 62.65% in 2024 and tumbled 4224.26% in 2026.
• Over 5 years, Cash from Investing Activities stood at -$632.0 million in 2022, then tumbled by 30.38% to -$824.0 million in 2023, then dropped by 5.1% to -$866.0 million in 2024, then declined by 5.43% to -$913.0 million in 2025, then climbed by 26.29% to -$673.0 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$673.0 million in Q2 2026, -$20.3 billion in Q1 2026, and -$913.0 million in Q4 2025.